Biology and clinical relevance of acute myeloid leukemia stem cells

Seminars in Hematology

Volumn 52, Issue 3, 2015, Pages 150-164

  Reinisch, Andreas ^a   Chan, Steven M ^a   Thomas, Daniel ^a   Majeti, Ravindra ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; 4 (2 AMINOETHYLAMINO) 1,8 DIMETHYLIMIDAZO[1,2 A]QUINOXALINE; 4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; 5 CHLORO N2 [1 (5 FLUORO 2 PYRIMIDINYL)ETHYL] N4 (5 METHYL 1H PYRAZOL 3 YL) 2,4 PYRIMIDINEDIAMINE; 5 FLUORO 2 [[1 (4 FLUOROPHENYL)ETHYL]AMINO] 6 [(5 METHYL 1H PYRAZOL 3 YL)AMINO] 3 PYRIDINECARBONITRILE; AEG 35156; ALISERTIB; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; APIGENIN; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BIRINAPANT; BORTEZOMIB; DASATINIB; DEQUALINIUM; FENRETINIDE; LESTAURTINIB; N TERT BUTYL 3 [5 METHYL 2 [4 (4 METHYL 1 PIPERAZINYL)PHENYLAMINO] 4 PYRIMIDINYLAMINO]BENZENESULFONAMIDE; NAVITOCLAX; NICLOSAMIDE; PARTHENOLIDE; QUIZARTINIB; RAPAMYCIN; RUXOLITINIB; SULINDAC; SUNITINIB; TANDUTINIB; TEMSIROLIMUS; TRIPTOLIDE; UNINDEXED DRUG; VENETOCLAX;

ACUTE MYELOBLASTIC LEUKEMIA; ARTICLE; BIOLOGICAL THERAPY; CANCER CHEMOTHERAPY; CANCER STEM CELL; ENZYME ACTIVITY; ERADICATION THERAPY; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; HEMATOPOIETIC STEM CELL; HUMAN; LEUKEMIA STEM CELL; LEUKEMOGENESIS; MINIMAL RESIDUAL DISEASE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LEUKEMIA, MYELOID, ACUTE; METABOLISM; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ANIMALS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKEMIA, MYELOID, ACUTE; NEOPLASTIC STEM CELLS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84937410267     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2015.03.008     Document Type: Review

References (104)

1. Dohner H., Estey E.H., Amadori S., et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010, 115:453-474.
2. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013, 368:2059-2074. Cancer Genome Atlas Research Network.
3. Mrozek K., Heerema N.A., Bloomfield C.D. Cytogenetics in acute leukemia. Blood Rev 2004, 18:115-136.
4. Grimwade D. The clinical significance of cytogenetic abnormalities in acute myeloid leukaemia. Best Pract Res Clin Haematol 2001, 14:497-529.
5. Patel J.P., Gonen M., Figueroa M.E., et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 2012, 366:1079-1089.
6. Metcalf D., Moore M.A., Warner N.L. Colony formation in vitro by myelomonocytic leukemic cells. J Natl Cancer Inst 1969, 43:983-1001.
7. Moore M.A., Williams N., Metcalf D. In vitro colony formation by normal and leukemic human hematopoietic cells: characterization of the colony-forming cells. J Natl Cancer Inst 1973, 50:603-623.
8. Dick J.E. Acute myeloid leukemia stem cells. Ann N Y Acad Sci 2005, 1044:1-5.
9. Lapidot T., Sirard C., Vormoor J., et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994, 367:645-648.
10. Bonnet D., Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997, 3:730-737.
11. Ailles L.E., Gerhard B., Hogge D.E. Detection and characterization of primitive malignant and normal progenitors in patients with acute myelogenous leukemia using long-term coculture with supportive feeder layers and cytokines. Blood 1997, 90:2555-2564.
12. Blair A., Hogge D.E., Ailles L.E., Lansdorp P.M., Sutherland H.J. Lack of expression of Thy-1 (CD90) on acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo. Blood 1997, 89:3104-3112.
13. Sarry J.E., Murphy K., Perry R., et al. Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rgammac-deficient mice. J Clin Invest 2011, 121:384-395.
14. Ishikawa F., Yoshida S., Saito Y., et al. Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol 2007, 25:1315-1321.
15. Kreso A., Dick J.E. Evolution of the cancer stem cell model. Cell Stem Cell 2014, 14:275-291.
16. Taussig D.C., Vargaftig J., Miraki-Moud F., et al. Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(-) fraction. Blood 2010, 115:1976-1984.
17. Goardon N., Marchi E., Atzberger A., et al. Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. Cancer Cell 2011, 19:138-152.
18. Reinisch A., Etchart N., Thomas D., et al. Epigenetic and in vivo comparison of diverse MSC sources reveals an endochondral signature for human hematopoietic niche formation. Blood 2015, 125(2):249-260.
19. Moshaver B., van Rhenen A., Kelder A., et al. Identification of a small subpopulation of candidate leukemia-initiating cells in the side population of patients with acute myeloid leukemia. Stem Cells 2008, 26:3059-3067.
20. Wulf G.G., Wang R.Y., Kuehnle I., et al. A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia. Blood 2001, 98:1166-1173.
21. Pearce D.J., Taussig D., Simpson C., et al. Characterization of cells with a high aldehyde dehydrogenase activity from cord blood and acute myeloid leukemia samples. Stem Cells 2005, 23:752-760.
22. Jan M., Chao M.P., Cha A.C., et al. Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker. Proc Natl Acad Sci U S A 2011, 108:5009-5014.
23. Jan M., Snyder T.M., Corces-Zimmerman M.R., et al. Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia. Sci Transl Med 2012, 4:149ra18.
24. Corces-Zimmerman M.R., Hong W.J., Weissman I.L., Medeiros B.C., Majeti R. Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. Proc Natl Acad Sci U S A 2014, 111:2548-2553.
25. Genovese G., Kahler A.K., Handsaker R.E., et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med 2014, 371(26):2477-2487.
26. Jaiswal S., Fontanillas P., Flannick J., et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med 2014, 371(26):2488-2498.
27. van Rhenen A., Feller N., Kelder A., et al. High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival. Clin Cancer Res 2005, 11:6520-6527.
28. Ran D., Schubert M., Pietsch L., et al. Aldehyde dehydrogenase activity among primary leukemia cells is associated with stem cell features and correlates with adverse clinical outcomes. Exp Hematol 2009, 37:1423-1434.
29. Gentles A.J., Plevritis S.K., Majeti R., Alizadeh A.A. Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia. JAMA 2010, 304:2706-2715.
30. Craddock C., Quek L., Goardon N., et al. Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia. Leukemia 2013, 27:1028-1036.
31. Jin L., Lee E.M., Ramshaw H.S., et al. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell 2009, 5:31-42.
32. Jaiswal S., Jamieson C.H., Pang W.W., et al. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell 2009, 138:271-285.
33. Majeti R., Chao M.P., Alizadeh A.A., et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 2009, 138:286-299.
34. Kikushige Y., Shima T., Takayanagi S., et al. TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells. Cell Stem Cell 2010, 7:708-717.
35. Hosen N., Park C.Y., Tatsumi N., et al. CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia. Proc Natl Acad Sci U S A 2007, 104:11008-11013.
36. van Rhenen A., van Dongen G.A., Kelder A., et al. The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells. Blood 2007, 110:2659-2666.
37. Saito Y., Kitamura H., Hijikata A., et al. Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells. Sci Transl Med 2010, 2(17):17ra9.
38. Askmyr M., Agerstam H., Hansen N., et al. Selective killing of candidate AML stem cells by antibody targeting of IL1RAP. Blood 2013, 121:3709-3713.
39. Majeti R. Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells. Oncogene 2011, 30:1009-1019.
40. Smith B.D., Roboz G.J., Walter R.B., et al. First-in man, phase 1 study of CSL362 (anti-IL3Rα/anti-CD123 monoclonal antibody) in patients with CD123+ acute myeloid leukemia (AML) in CR at high risk for early relapse. Blood 2014, 124:120.
41. Burnett A.K., Hills R.K., Hunter A.E., et al. The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison. Leukemia 2013, 27:75-81.
42. Kung Sutherland M.S., Walter R.B., Jeffrey S.C., et al. SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood 2013, 122:1455-1463.
43. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006, 441:431-436.
44. Guzman M.L., Neering S.J., Upchurch D., et al. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 2001, 98:2301-2307.
45. Birkenkamp K.U., Geugien M., Schepers H., Westra J., Lemmink H.H., Vellenga E. Constitutive NF-kappaB DNA-binding activity in AML is frequently mediated by a Ras/PI3-K/PKB-dependent pathway. Leukemia 2004, 18:103-112.
46. Takahashi S., Harigae H., Ishii K.K., et al. Over-expression of Flt3 induces NF-kappaB pathway and increases the expression of IL-6. Leuk Res 2005, 29:893-899.
47. Kagoya Y., Yoshimi A., Kataoka K., et al. Positive feedback between NF-kappaB and TNF-alpha promotes leukemia-initiating cell capacity. J Clin Invest 2014, 124:528-542.
48. Bosman M.C., Schepers H., Jaques J., et al. The TAK1-NF-kappaB axis as therapeutic target for AML. Blood 2014, 124:3130-3140.
49. Guzman M.L., Rossi R.M., Karnischky L., et al. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood 2005, 105:4163-4169.
50. Guzman M.L., Yang N., Sharma K.K., et al. Selective activity of the histone deacetylase inhibitor AR-42 against leukemia stem cells: a novel potential strategy in acute myelogenous leukemia. Mol Cancer Ther 2014, 13:1979-1990.
51. Jin Y., Lu Z., Ding K., et al. Antineoplastic mechanisms of niclosamide in acute myelogenous leukemia stem cells: inactivation of the NF-kappaB pathway and generation of reactive oxygen species. Cancer Res 2010, 70:2516-2527.
52. Guzman M.L., Rossi R.M., Neelakantan S., et al. An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood 2007, 110:4427-4435.
53. Guzman M.L., Swiderski C.F., Howard D.S., et al. Preferential induction of apoptosis for primary human leukemic stem cells. Proc Natl Acad Sci U S A 2002, 99:16220-16225.
54. Volk A., Li J., Xin J., et al. Co-inhibition of NF-kappaB and JNK is synergistic in TNF-expressing human AML. J Exp Med 2014, 211:1093-1108.
55. Dai Y., Guzman M.L., Chen S., et al. The NF (Nuclear factor)-kappaB inhibitor parthenolide interacts with histone deacetylase inhibitors to induce MKK7/JNK1-dependent apoptosis in human acute myeloid leukaemia cells. Br J Haematol 2010, 151:70-83.
56. Chan S.M., Majeti R. Role of DNMT3A, TET2, and IDH1/2 mutations in pre-leukemic stem cells in acute myeloid leukemia. Int J Hematol 2013, 98:648-657.
57. Corces-Zimmerman M.R., Majeti R. Pre-leukemic evolution of hematopoietic stem cells: the importance of early mutations in leukemogenesis. Leukemia 2014, 28:2276-2282.
58. Zuber J., Shi J., Wang E., et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 2011, 478:524-528.
59. Herrmann H., Blatt K., Shi J., et al. Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia AML. Oncotarget 2012, 3:1588-1599.
60. Fiskus W., Sharma S., Qi J., et al. BET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITD. Mol Cancer Ther 2014, 13:2315-2327.
61. Fiskus W., Sharma S., Qi J., et al. Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells. Mol Cancer Ther 2014, 13:1142-1154.
62. Zou Z., Huang B., Wu X., et al. Brd4 maintains constitutively active NF-kappaB in cancer cells by binding to acetylated RelA. Oncogene 2014, 33:2395-2404.
63. Ni Chonghaile T., Letai A. Mimicking the BH3 domain to kill cancer cells. Oncogene 2008, 27(Suppl 1):S149-S157.
64. Glaser S.P., Lee E.F., Trounson E., et al. Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia. Genes Dev 2012, 26:120-125.
65. Bose P., Grant S. Mcl-1 as a therapeutic target in acute myelogenous leukemia (AML). Leuk Res Rep 2013, 2:12-14.
66. Chen R., Keating M.J., Gandhi V., Plunkett W. Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death. Blood 2005, 106:2513-2519.
67. Thomas D., Powell J.A., Vergez F., et al. Targeting acute myeloid leukemia by dual inhibition of PI3K signaling and Cdk9-mediated Mcl-1 transcription. Blood 2013, 122:738-748.
68. Campos L., Sabido O., Rouault J.P., Guyotat D. Effects of BCL-2 antisense oligodeoxynucleotides on in vitro proliferation and survival of normal marrow progenitors and leukemic cells. Blood 1994, 84:595-600.
69. Keith F.J., Bradbury D.A., Zhu Y.M., Russell N.H. Inhibition of bcl-2 with antisense oligonucleotides induces apoptosis and increases the sensitivity of AML blasts to Ara-C. Leukemia 1995, 9:131-138.
70. Marcucci G., Byrd J.C., Dai G., et al. Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. Blood 2003, 101:425-432.
71. Marcucci G., Stock W., Dai G., et al. Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity. J Clin Oncol 2005, 23:3404-3411.
72. Oltersdorf T., Elmore S.W., Shoemaker A.R., et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005, 435:677-681.
73. Tse C., Shoemaker A.R., Adickes J., et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008, 68:3421-3428.
74. Konopleva M., Contractor R., Tsao T., et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 2006, 10:375-388.
75. Lagadinou E.D., Sach A., Callahan K., et al. BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell 2013, 12:329-341.
76. Chen Z.X., Pervaiz S. Bcl-2 induces pro-oxidant state by engaging mitochondrial respiration in tumor cells. Cell Death Differ 2007, 14:1617-1627.
77. Roberts A.W., Seymour J.F., Brown J.R., et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol 2012, 30:488-496.
78. Mason K.D., Carpinelli M.R., Fletcher J.I., et al. Programmed anuclear cell death delimits platelet life span. Cell 2007, 128:1173-1186.
79. Schoenwaelder S.M., Jarman K.E., Gardiner E.E., et al. Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets. Blood 2011, 118:1663-1674.
80. Souers A.J., Leverson J.D., Boghaert E.R., et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 2013, 19:202-208.
81. Pan R., Hogdal L.J., Benito J.M., et al. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov 2014, 4:362-375.
82. Chan S.M., Thomas D., Corces-Zimmerman M.R., et al. Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nat Med 2015, 2(2):178-184.
83. Ward P.S., Patel J., Wise D.R., et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 2010, 17:225-234.
84. Skrtic M., Sriskanthadevan S., Jhas B., et al. Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia. Cancer Cell 2011, 20:674-688.
85. Artandi S.E., DePinho R.A. Telomeres and telomerase in cancer. Carcinogenesis 2010, 31:9-18.
86. Harley C.B. Telomerase and cancer therapeutics. Nat Rev Cancer 2008, 8:167-179.
87. Bruedigam C., Bagger F.O., Heidel F.H., Paine Kuhn C., Guignes S., Song A., et al. Telomerase inhibition effectively targets mouse and human AML stem cells and delays relapse following chemotherapy. Cell Stem Cell 2014, 15:775-790.
88. Schofield R. The relationship between the spleen colony-forming cell and the haemopoietic stem cell. Blood Cells 1978, 4:7-25.
89. Mendelson A., Frenette P.S. Hematopoietic stem cell niche maintenance during homeostasis and regeneration. Nat Med 2014, 20:833-846.
90. Friedenstein A.J., Chailakhyan R.K., Latsinik N.V., Panasyuk A.F. Keiliss-Borok IV. Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues. Cloning in vitro and retransplantation in vivo. Transplantation 1974, 17:331-340.
91. Kuznetsov S.A., Krebsbach P.H., Satomura K., et al. Single-colony derived strains of human marrow stromal fibroblasts form bone after transplantation in vivo. J Bone Miner Res 1997, 12:1335-1347.
92. Chan C.K., Chen C.C., Luppen C.A., et al. Endochondral ossification is required for haematopoietic stem-cell niche formation. Nature 2009, 457:490-494.
93. Tavassoli M., Crosby W.H. Transplantation of marrow to extramedullary sites. Science 1968, 161:54-56.
94. Sipkins D.A., Wei X., Wu J.W., et al. In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment. Nature 2005, 435:969-973.
95. Ninomiya M., Abe A., Katsumi A., et al. Homing, proliferation and survival sites of human leukemia cells in vivo in immunodeficient mice. Leukemia 2007, 21:136-142.
96. Jin L., Hope K.J., Zhai Q., Smadja-Joffe F., Dick J.E. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med 2006, 12:1167-1174.
97. Raaijmakers M.H., Mukherjee S., Guo S., et al. Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature 2010, 464:852-857.
98. Walkley C.R., Olsen G.H., Dworkin S., et al. A microenvironment-induced myeloproliferative syndrome caused by retinoic acid receptor gamma deficiency. Cell 2007, 129:1097-1110.
99. Kode A., Manavalan J.S., Mosialou I., et al. Leukaemogenesis induced by an activating beta-catenin mutation in osteoblasts. Nature 2014, 506:240-244.
100. Schepers K., Pietras E.M., Reynaud D., et al. Myeloproliferative neoplasia remodels the endosteal bone marrow niche into a self-reinforcing leukemic niche. Cell Stem Cell 2013, 13:285-299.
101. Arranz L., Sanchez-Aguilera A., Martin-Perez D., et al. Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms. Nature 2014, 512:78-81.
102. Zeng Z., Shi Y.X., Samudio I.J., et al. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood 2009, 113:6215-6224.
103. Nervi B., Ramirez P., Rettig M.P., et al. Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. Blood 2009, 113:6206-6214.
104. Tabe Y., Shi Y.X., Zeng Z., et al. TGF-beta-neutralizing antibody 1D11 enhances cytarabine-induced apoptosis in AML cells in the bone marrow microenvironment. PLoS One 2013, 8:e62785.